Antimicrobial Agents and Chemotherapy · 2015 · 23 citations · 32 references
MedicinePharmacologyPharmacotherapyBioavailabilityBiochemical PharmacologyChemotherapyAntiparasitic AgentsAntiparasitic ChemotherapyAntiparasitic PharmacologyAntiparasitic PharmacotherapyAntiparasitic TherapyMalariaAntimalarial AgentsAntimalarial ChemotherapyAntimalarial Drug CombinationsAntimalarial Drug DevelopmentHerbal SupplementsIn Vivo Efficacy TestingPlasmodium FalciparumTreatment Of Malaria
5-Aminolevulinic acid (ALA) is a naturally occurring amino acid present in diverse organisms and a precursor of heme biosynthesis. ALA is commercially available as a component of cosmetics, dietary supplements, and pharmaceuticals for cancer diagnosis and therapy. Recent reports demonstrated that the combination of ALA and ferrous ion (Fe(2+)) inhibits the in vitro growth of the human malaria parasite Plasmodium falciparum. To further explore the potential application of ALA and ferrous ion as a combined antimalarial drug for treatment of human malaria, we conducted an in vivo efficacy evaluation. Female C57BL/6J mice were infected with the lethal strain of rodent malaria parasite Plasmodium yoelii 17XL and orally administered ALA plus sodium ferrous citrate (ALA/SFC) as a once-daily treatment. Parasitemia was monitored in the infected mice, and elimination of the parasites was confirmed using diagnostic PCR. Treatment of P. yoelii 17XL-infected mice with ALA/SFC provided curative efficacy in 60% of the mice treated with ALA/SFC at 600/300 mg/kg of body weight; no mice survived when treated with vehicle alone. Interestingly, the cured mice were protected from homologous rechallenge, even when reinfection was attempted more than 230 days after the initial recovery, indicating long-lasting resistance to reinfection with the same parasite. Moreover, parasite-specific antibodies against reported vaccine candidate antigens were found and persisted in the sera of the cured mice. These findings provide clear evidence that ALA/SFC is effective in an experimental animal model of malaria and may facilitate the development of a new class of antimalarial drug.
32
Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria
Arjen M. Dondorp, François Nosten, Poravuth Yi et al. · New England Journal of Medicine · 2009 · 3.5K citations · Full text
Emmanuel B. Bache, Sélidji Todagbé Agnandji, Bertrand Lell et al. · The Lancet · 2015 · 671 citations
The effect of air pollution on human physiological function in China: a longitudinal study
Yuming Guo, Shanshan Li, Yong Zhou et al. · The Lancet · 2015 · 424 citations
Michael Korsinczky, Nanhua Chen, Barbara Kotecka et al. · Antimicrobial Agents and Chemotherapy · 2000 · 379 citations · Full text